Annual Report

The report highlights the Group's 14.4% revenue growth in 2023-24, alongside an expansion of its export footprint to 50 countries. The company launched 47 new products during the year and added 15 bio-equivalent products, bringing its portfolio to 78. These developments accompanied growth across its pharmaceutical, animal health, and agro-based businesses.